根据《上市公司独立董事管理办法》、《深圳证券交易所上市公司自律监管指 引第 1 号——主板上市公司规范运作》、《上市公司治理准则》等相关法律、法规 和规范性文件的规定，根据《公司章程》、《独立董事工作制度》等相关制度要求， 我们作为公司的独立董事，对公司第七届董事会第十九次会议审议的对外投资暨 关联交易事项发表独立意见如下： 此次对外投资标的具有一定稀缺性，且属于国家重点发展行业领域，交易方 案合理、切实可行，有利于提高公司的资产质量和自有资金使用效率，符合公司 和全体股东的利益。 我们已对本次交易事项予以事前认可，董事会在审议关联交易事项时，关联 董事回避了表决，投资的决策与审议程序符合《公司法》、《深圳证券交易所股票 上市规则》和《公司章程》等相关规定。此次关联交易事项是公司正常对外投资 所需，关联交易价格公允，大股东控制的基金管理人收取费用符合行业惯例，不 存在损害公司及全体股东利益的情况。 宏达高科控股股份有限公司 基于上述情况，我们对公司本次进行对外投资暨关联交易事项发表同意的独 立意见。 独立董事关于公司进行对外投资暨关联交易事项的独 立意见 （此页无正文，为宏达高科控股股份有限公司独立董事关于对 ...

证券代码：002144 股票简称：宏达高科 公告编号：2023-024 宏达高科控股股份有限公司 关于公司进行对外投资暨关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、本次对外投资暨关联交易概述 1、本次投资的基本情况 为抓住新能源车行业发展机遇，提高公司自有资金的使用效率，并增强 公司与新能源车产业链的联系，宏达高科控股股份有限公司（以下简称"公 司"）拟以 0 元购买关联方宏达控股集团有限公司（以下简称"宏达集团"） 认缴且未实际出资的嘉兴迪鑫创业投资合伙企业（有限合伙）（以下简称"嘉 兴迪鑫"）的 5100 万元人民币（下同）有限合伙人份额。之后公司将就该部 分 5100 万元认购份额进行实际出资。嘉兴迪鑫是专为完成此次对外投资设立 的单一目的基金，拟以不超过人民币 20,000 万元，向独立第三方购买国内某 家车规级半导体行业头部企业的部分股权。 根据拟签署的合伙协议，公司出资额 5100 万元中包括了向嘉兴迪鑫的执 行事务合伙人暨关联方杭州宏达君合资产管理有限公司（以下简称"宏达君 合"）一次性支付管理费用 100 万元，剩余 5 ...

宏达高科控股股份有限公司 独立董事关于公司进行对外投资暨关联交易事项的事 前认可意见 根据《上市公司独立董事管理办法》、《深圳证券交易所上市公司自律监管指 引第 1 号——主板上市公司规范运作》、《上市公司治理准则》等相关法律、法规 和规范性文件的规定，根据《公司章程》、《独立董事工作制度》等相关制度要求， 我们作为公司的独立董事，对拟提交公司第七届董事会第十九次会议审议的相关 事项发表事前认可意见如下： 此次对外投资标的具有一定稀缺性，且属于国家重点发展行业领域，交易方 案合理、切实可行，有利于提高公司的资产质量和自有资金使用效率，符合公司 和全体股东的利益。本次对外投资符合法律法规、规章及规范性文件的相关规定， 且不构成重大资产重组。按照相关规定，本次交易构成关联交易，公司董事会会 议在审议本议案时，关联董事应依法回避表决。 此次关联交易事项是公司正常对外投资所需，关联交易价格公允，公司大股 东控制的基金管理人收取的管理费用符合行业惯例，没有损害公司和非关联股东 的利益，不存在损害公司及全体股东利益的情况。 2023 年 9 月 11 日 （此页无正文，为宏达高科控股股份有限公司独立董事关于对外投资 暨关 ...

证券代码：002144 股票简称：宏达高科 公告编号：2023-022 宏达高科控股股份有限公司 第七届董事会第十九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 1、以 7 票同意、0 票反对、0 票弃权的表决结果审议通过了《关于公司进 行对外投资暨关联交易的议案》。 审议该议案时，因公司董事长沈国甫先生，副董事长沈珺先生分别担任交易 对手方宏达控股集团有限公司的董事长和总经理，故关联董事沈国甫先生、沈珺 先生回避该事项表决。 本次董事会同意以 0 元购买关联方宏达控股集团有限公司认缴且未实际出 资的嘉兴迪鑫创业投资合伙企业（有限合伙）（以下简称"嘉兴迪鑫"）的 5100 万元人民币（下同）有限合伙人份额。之后公司将就该部分 5100 万元认购份 额进行实际出资。嘉兴迪鑫是专为完成此次对外投资设立的单一目的基金， 拟以不超过人民币 20,000 万元，向独立第三方购买国内某家车规级半导体行 业头部企业的部分股权。具体情况详见同日披露于证券时报和巨潮资讯网的《关 于公司进行对外投资暨关联交易的公告》。 备查文件：公司第七届董事会第十九次会议决议 ...

本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 宏达高科控股股份有限公司（以下简称"公司"）第七届监事会第十八次会 议通知于 2023 年 9 月 6 日通过电子邮件方式向各监事发出，会议于 2023 年 9 月 11 日上午十一点在浙江省海宁市许村镇建设路 118 号公司会议室召开，会议应 参加监事 3 名，实际参加监事 3 名。会议的召开符合《公司法》和《公司章程》 规定，决议合法有效。会议由监事会主席张建福先生主持，会议审议并通过如下 决议： 证券代码：002144 股票简称：宏达高科 公告编号：2023-023 宏达高科控股股份有限公司 第七届监事会第十八次会议决议公告 1、以 2 票同意、0 票反对、0 票弃权的表决结果审议通过了《关于公司进行 对外投资暨关联交易的议案》。因张建福先生担任本次关联交易对手方宏达控股 集团有限公司董事，因此属于关联监事，回避本议案的表决。 监事会发表了以下意见： 经审核，监事会认为公司本次进行对外投资暨关联交易事项有利于提高公司 的资产质量和自有资金使用效率，符合公司和全体股东的利益，符合公司的战略 布局及发展需求。本 ...

证券代码：002144 股票简称：宏达高科 公告编号：2023-021 宏达高科控股股份有限公司 关于公司获得温室气体核查声明和产品碳足迹核查声明书 的公告 公司全面落实国家绿色低碳发展战略，勇于担当社会责任，积极探索在纺 织面料领域中节能降碳的科学技术及生产工艺，从而降低产业能耗，提高企业 经济效益。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，宏达高科控股股份有限公司（以下简称"公司"）获得了通标标准技 术服务有限公司（以下简称"SGS"）颁发的温室气体核查声明和产品碳足迹核 查声明书。 SGS依据ISO 14064-3:2019《温室气体声明审定与核查的规范及指南》，并在 满足ISO 14064-1:2018《组织层次上对温室气体排放和清除的量化和报告的规范 及指南》的要求下，对公司2022年度的温室气体盘查清册进行核查，出具了无 保留意见的温室气体核查声明。 公司获得碳足迹核查认证的产品为汽车内饰复合面料及针织服装面料产 品，取得的声明书编号分别为CN23/00004293和CN23/00004294。以上两项产品 的碳足迹认证经SGS核查计 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥249,239,367.47, a decrease of 8.84% compared to ¥273,423,542.60 in the same period last year[25]. - Net profit attributable to shareholders increased by 12.08% to ¥48,364,692.69 from ¥43,152,169.43 year-on-year[25]. - The net cash flow from operating activities surged by 197.01% to ¥33,081,691.19, compared to ¥11,138,081.95 in the previous year[25]. - Basic and diluted earnings per share rose by 12.09% to ¥0.2736 from ¥0.2441 in the same period last year[25]. - Total assets at the end of the reporting period were ¥2,228,655,695.00, reflecting a 2.92% increase from ¥2,165,349,466.00 at the end of the previous year[25]. - The net assets attributable to shareholders increased by 1.71% to ¥1,979,839,031.14 from ¥1,946,575,091.25 at the end of the previous year[25]. - The company reported a total profit for the first half of 2023 of CNY 53,039,790.55, compared to CNY 46,920,717.12 in the same period last year, marking a growth of 6.5%[1]. - The total comprehensive income for the first half of 2023 was CNY 51,203,963.69, compared to CNY 37,295,210.86 in the previous year, reflecting a growth of 37.4%[132]. Revenue Segmentation - The fabric weaving segment generated CNY 164.71 million, accounting for 66.09% of total revenue, reflecting an increase of 11.77% year-on-year[40]. - The medical device segment reported revenue of CNY 32.35 million, up 8.12% year-on-year, contributing 12.98% to total revenue[40]. - The total revenue for the transportation fabric segment reached ¥95,968,384.17, representing a 32.62% increase compared to the previous year[42]. - Domestic revenue accounted for 69.12% of total revenue, increasing by 6.35% year-on-year, while international revenue decreased by 30.93% to 30.88% of total revenue[42]. Cash Flow and Liquidity - The company’s cash flow from operating activities increased significantly by 197.01% to CNY 33.08 million, primarily due to the recovery of receivables[39]. - The company reported a cash inflow from sales of goods and services of CNY 265,056,907.26 in the first half of 2023, compared to CNY 249,322,117.63 in the first half of 2022, which is an increase of about 6.3%[138]. - The cash outflow for purchasing goods and services decreased to CNY 168,454,373.28 in the first half of 2023 from CNY 206,940,201.46 in the same period of 2022, a reduction of approximately 18.6%[138]. - The total cash and cash equivalents at the end of the first half of 2023 amounted to CNY 595,005,947.02, up from CNY 457,162,762.71 at the end of the first half of 2022, marking an increase of approximately 30.2%[139]. Research and Development - Research and development expenses rose by 32.50% to CNY 13.37 million, indicating a strong focus on innovation[39]. - The company’s subsidiary, Weirder, has developed over 120 patents related to ultrasound diagnosis and treatment, showcasing its strong R&D capabilities[35]. - The company has initiated a new technology research and development program aimed at enhancing product offerings and improving operational efficiency[144]. Market Expansion and Strategy - The company is actively expanding into the new energy vehicle and high-end passenger vehicle markets, enhancing its product offerings[38]. - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[1]. - The company plans to expand its market presence by entering three new regions by the end of 2023[149]. - New product launches are expected to contribute an additional 20% to revenue in the next quarter[148]. Environmental and Regulatory Compliance - In the first half of 2023, the company incurred wastewater treatment costs of 1.78 million yuan, air pollution control costs of 1.025 million yuan, and solid waste disposal costs of 240,000 yuan[79]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[80]. - The company plans to complete the third revision of its emergency response plan for environmental incidents by October 2023[78]. Shareholder Information - The total number of shares is 176,762,528, with 21.99% being limited shares and 78.01% being unrestricted shares[107]. - The largest shareholder, Shen Guofu, holds 23.36% of the shares, totaling 41,294,390 shares[109]. - The company reported a profit distribution of CNY 17,676,252.80 to shareholders during the current period[152]. Risk Factors - The company is exposed to risks related to macroeconomic conditions, downstream market trends, and raw material prices in the textile industry[5]. - The company faces market competition risks in its textile and medical device sectors, influenced by global economic fluctuations and increasing competition from multinational corporations[64]. - The company is exposed to risks from raw material price fluctuations, which could impact production costs[65]. - As the company expands its business, accounts receivable are expected to increase, posing risks of bad debts if major clients face operational difficulties[66]. Financial Management and Reporting - The semi-annual financial report was not audited[87]. - The financial statements reflect the company's financial position, operating results, and cash flows accurately, adhering to enterprise accounting standards[160]. - The company has implemented strict measures to protect its core technologies in the medical device sector, mitigating risks of technology leakage[65].

证券代码：002144 股票简称：宏达高科 公告编号：2023-015 宏达高科控股股份有限公司 关于举办投资者接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 宏达高科控股股份有限公司（以下简称"公司"）已于 2023年 4月 26 日披露《2022 年年度报告及其摘要》，为便于广大投资者深入全面地了解公司情况，公司将举办投资 者接待日活动，现将有关事项公告如下： 1、接待时间 2023 年 5 月 25 日 15:30-16:30 2、接待方式 采用现场接待方式 3、接待地点 浙江省海宁市许村镇建设路 118 号宏达高科控股股份有限公司三楼会议室 4、登记预约方式 请来访投资者于 2023 年 5 月 22 日至 23 日工作时间与公司证券部联系，并同时提 供调研提纲，以便接待登记和安排。 联系人：沈婷婷； 电话：0573-87566909；传真：0573-87552681。 5、公司出席人员 公司董事长沈国甫先生、独立董事平衡先生、总经理许建舟先生、财务总监王凤 娟女士、董事会秘书马强强先生（如有特殊情况，参与人员会有调整）。 6、注意事 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥120,153,487.21, representing a 3.21% increase compared to ¥116,414,221.46 in the same period last year[4] - Net profit attributable to shareholders was ¥17,223,917.74, reflecting a 10.72% increase from ¥15,555,857.99 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥16,603,160.43, which is a 25.64% increase from ¥13,215,162.48 in the previous year[4] - The total operating revenue for Q1 2023 was CNY 120,153,487.21, an increase from CNY 116,414,221.46 in the previous period, representing a growth of approximately 2.5%[15] - The net profit for Q1 2023 was CNY 17,522,185.87, an increase of 13.3% compared to CNY 15,488,115.00 in Q1 2022[16] - Operating profit for the quarter reached CNY 19,705,509.83, up from CNY 17,153,491.13, reflecting a growth of 14.9% year-over-year[16] - Total comprehensive income for Q1 2023 was CNY 19,325,035.87, significantly higher than CNY 5,443,665.00 in the same period last year[16] - Basic earnings per share for Q1 2023 were CNY 0.10, up from CNY 0.09 in Q1 2022, reflecting a growth of 11.1%[16] Cash Flow and Assets - The company's cash flow from operating activities decreased by 16.37% to ¥16,636,610.36, down from ¥19,892,602.11 in the same quarter last year[4] - Cash flow from operating activities generated a net amount of CNY 16,636,610.36, down from CNY 19,892,602.11 in Q1 2022, indicating a decrease of 11.3%[18] - Cash and cash equivalents at the end of Q1 2023 totaled CNY 512,266,644.24, compared to CNY 474,457,318.97 at the end of Q1 2022, showing an increase of 8.0%[19] - The net increase in cash and cash equivalents was -¥17,530,104.83, a decrease of 121.08% compared to an increase of ¥83,168,102.30 in the previous year[8] - Cash and cash equivalents at the end of the period were CNY 548,102,286.98, slightly up from CNY 538,553,452.28 at the beginning of the year[12] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥2,149,867,938.58, a decrease of 0.71% from ¥2,165,349,466.00 at the end of the previous year[4] - The total assets as of March 31, 2023, were CNY 2,149,867,938.58, down from CNY 2,165,349,466.00 at the beginning of the year[14] - The total liabilities decreased to CNY 179,096,919.64 from CNY 213,903,482.93, showing a decline of about 16.3%[14] - The total equity attributable to shareholders increased to CNY 1,965,601,858.99 from CNY 1,946,575,091.25, reflecting a growth of approximately 1.0%[14] Expenses and Investments - The total operating costs decreased to CNY 106,830,552.14 from CNY 109,850,025.97, reflecting a reduction of about 2.8%[15] - Research and development expenses increased to CNY 6,559,933.54, up from CNY 5,184,920.83, indicating a rise of approximately 26.5%[15] - The company reported a decrease in cash inflow from investment activities, with a net cash flow of -CNY 2,828,433.91 compared to CNY 62,553,193.26 in the previous year[19] - The company reported a net investment income of CNY 4,051,036.65, down from CNY 5,974,979.15, representing a decrease of approximately 32.2%[15] - The company experienced a significant increase in financial expenses, amounting to -¥970,017.78, primarily due to increased interest income[7] - The company experienced a significant increase in credit impairment losses, amounting to CNY 1,380,454.52, compared to CNY 2,828,371.43 in the previous year[16] Receivables and Inventory - Accounts receivable decreased by 32.56% to ¥84,951,418.77, down from ¥125,956,911.98 in the previous year[7] - The accounts receivable decreased to CNY 84,951,418.77 from CNY 125,956,911.98, a reduction of approximately 32.5%[12] - The inventory level decreased to CNY 99,947,943.11 from CNY 105,968,149.33, indicating a decline of about 5.7%[12] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 20,235[9] - The company reported a tax expense of CNY 2,133,700.40 for the quarter, compared to CNY 1,280,012.86 in the same period last year, indicating an increase of 66.7%[16]

宏达高科控股股份有限公司 Hongda High-Tech Holding Co.,Ltd. （002144） 2022 年年度报告 2023 年 4 月 宏达高科控股股份有限公司2022年年度报告全文 第一节 重要提示、目录和释义 ...